EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Efficacy and safety of branded vs generic lacosamide in epilepsy: a retrospective real-world study

Giuseppe Salafica, Diana Tilenni, Attilio Vinaccia, Giovanni Tripepi, Chiara Martellino, Salvatore Maria Lima, Giorgia Atanasio, Fabio Lamanna, Orazio Pardeo, Mariangela Panebianco, Angelina Laganà, Angelo Labate

Neurological Sciences · 2025

DOI: 10.1007/s10072-025-08563-3 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Neurological Sciences, 2025. Verfasst von Giuseppe Salafica und 11 weiteren Autor:innen. Beteiligte Einrichtung: Neurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. Hauptthemen laut MEDLINE: Lacosamide, Anticonvulsants, Drugs, Generic, Epilepsy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Palermo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Lacosamide (LCS) is a third-generation antiseizure medication (ASM) approved for focal-onset seizures and generalized epilepsy. Although the branded formulation, Vimpat ® , has shown efficacy and safety, the introduction of generic versions, such as Stutan ® , raises concerns about clinical equivalence, especially considering the potential for therapeutic fluctuations that could result in breakthrough seizures or adverse events. This study aimed to compare the real-world efficacy, safety and tolerability of branded lacosamide (Vimpat ® ) versus its generic counterpart (Stutan ® ) in patients with focal or generalized epilepsy.

Methods

A multicenter, retrospective, observational study was conducted at two epilepsy centers in Southern Italy. Sixty adult patients were included and divided into two groups: Group A ( n = 30) received branded LCS and Group B ( n = 30) received the generic formulation. Data were collected at treatment initiation (T0) and the first follow-up (T1), including seizure frequency, adverse events and dose adjustments. The primary outcome was the responder rate (≥ 50% reduction in seizure frequency), with secondary outcomes including seizure freedom, adverse events and dose changes.

Results

Baseline characteristics were similar between groups. The average daily LCS dose was significantly higher in the Vimpat ® group (275 ± 121 mg) compared to the Stutan ® group (168 ± 89 mg, p < 0.001). Despite this, efficacy outcomes were comparable, with 60.0% of patients in Group A and 43.3% in Group B achieving a ≥ 50% seizure reduction ( p = 0.08). Adverse events were mild or moderate.

Conclusions

In this real-world setting, generic LCS (Stutan ® ) demonstrated comparable efficacy, safety and tolerability to Vimpat ® , supporting its clinical use as a valid alternative in epilepsy management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LacosamideAnticonvulsantsDrugs, GenericEpilepsyEpilepsies, PartialHumansMaleFemaleRetrospective StudiesMiddle AgedAdultTreatment OutcomeAgedItalyYoung Adult

Stichwörter der Autor:innen

EpilepsyGeneric formulationLacosamideReal-world study

Substanzen

LacosamideAnticonvulsantsDrugs, Generic

Autor:innen und Institutionen

  • Neurophysiopatology and Movement Disorders Clinic, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.
  • National Research Council (CNR), Institute of Clinical Physiology (IFC), Clinical Epidemiology of Renal Diseases and Hypertension, Ospedali Riuniti, Reggio Calabria, Italy.
  • Department of Biomedicine, Neuroscience, and Advanced Diagnostic (BIND), University of Palermo, Palermo, Italy.
  • Neurology and Stroke Unit-ARNAS Garibaldi, Catania, Italy.
  • Neurology Clinic, University of Palermo, Palermo, Italy. labate270273@gmail.com.

Förderung

  • Università degli Studi di Palermo

Zitieren

APA

Salafica, G., Tilenni, D., Vinaccia, A., Tripepi, G., Martellino, C., Lima, S. M., Atanasio, G., Lamanna, F., Pardeo, O., Panebianco, M., Laganà, A., & Labate, A. (2025). Efficacy and safety of branded vs generic lacosamide in epilepsy: a retrospective real-world study. Neurological Sciences. https://doi.org/10.1007/s10072-025-08563-3

Vancouver

Salafica G, Tilenni D, Vinaccia A, Tripepi G, Martellino C, Lima SM, et al. Efficacy and safety of branded vs generic lacosamide in epilepsy: a retrospective real-world study. Neurological Sciences. 2025. doi:10.1007/s10072-025-08563-3

BibTeX
@article{Salafica2025,
  author = {Salafica, Giuseppe and Tilenni, Diana and Vinaccia, Attilio and Tripepi, Giovanni and Martellino, Chiara and Lima, Salvatore Maria and Atanasio, Giorgia and Lamanna, Fabio and Pardeo, Orazio and Panebianco, Mariangela and Laganà, Angelina and Labate, Angelo},
  title = {Efficacy and safety of branded vs generic lacosamide in epilepsy: a retrospective real-world study},
  journal = {Neurological Sciences},
  year = {2025},
  doi = {10.1007/s10072-025-08563-3}
}
Kostenlos starten →